The Pittsburgh Scientific and Data Research Center for the COPE-AKI Consortium (Pitt-SDRC)

摘要 急性肾损伤（阿基）和慢性肾病（CKD）是“相互关联”的综合征， 它们相互影响。CKD是阿基的风险因素，阿基有助于 慢性肾脏病（CKD）、终末期肾病（ESRD）、心血管症状的发生或进展， 和死亡，更不用说复发性阿基发作和健康相关生活质量受损 （HRQoL）。阿基住院后的护理过程被发现是次优的， 护理缺乏连续性，后续行动延迟，药物管理欠佳 加剧了不良后果的风险。此外，最佳的药物治疗，如 阻断肾素-血管紧张素-醛固酮系统（RAAS）或钠-葡萄糖协同转运蛋白 2型（SGLT 2）尚未定义。门诊急性肾损伤患者的护理 （COPE-AKI）联盟将解决这些重要的知识差距， 管理中度（2期）或重度（3期）阿基发作后存活的患者。的 COPE-AKI联盟的目标是开发和测试干预措施， 护理过程，并确定关键的药物和非药物干预措施， 降低这些高危患者的发病率。临床试验和数据中心 匹兹堡大学的协调（CCDC）已经做好准备， COPE-AKI联盟的数据研究中心（SDRC）。我们的多学科 调查小组有着合作的历史、丰富的经验和专业知识，包括 在急性和慢性肾脏疾病、重症和转化护理、药物治疗方面的专业知识 管理、临床试验设计、远程医疗、临床和数据协调、项目 管理支持，生物统计学，患者报告结局的测量，健康 服务研究和患者参与。我们的目标是作为科学和数据 COPE-AKI联盟的研究中心。具体而言，我们将1）建立一个有效的， 设计联盟研究的严格流程，包括方案制定和 调整现有的网络数据收集系统; 2）提供全面的专门知识 在联合体内进行数据管理和分析;以及3）提供项目协调 在研究的所有阶段提供行政支持。

ABSTRACT Acute kidney injury (AKI) and chronic kidney disease (CKD) are “interconnected” syndromes in which each influences the other. CKD is a risk factor for AKI and AKI contributes to the development or progression of CKD, end-stage renal disease (ESRD), cardiovascular symptoms, and death, not to mention recurrent AKI episodes and impaired health-related quality of life (HRQoL). Processes of care after AKI hospitalization have been found to be suboptimal, with lack of continuity of care, delayed follow-up and suboptimal medication management exacerbating the risks of adverse outcomes. In addition, optimal pharmacologic therapy, such as blockade of the renin-angiotensin-aldosterone system (RAAS) or sodium-glucose cotransporter type 2 (SGLT2), has not been defined. The Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Consortium will address these important gaps in knowledge of optimal management of patients surviving an episode of moderate (stage 2) or severe (stage 3) AKI. The goal of the COPE-AKI Consortium will be to develop and test interventions to optimize processes of care and identify key pharmacologic and non-pharmacologic interventions to reduce morbidity among these high-risk patients. The Center for Clinical Trials & Data Coordination (CCDC) at the University of Pittsburgh is well poised to serve as the Scientific and Data Research Center (SDRC) for the COPE-AKI Consortium. Our multidisciplinary investigative team has a history of collaboration, wealth of experience and expertise, including expertise in acute and chronic kidney disease, critical and translational care, medication management, design of clinical trials, telehealth, clinical and data coordination, project administration support, biostatistics, measurement of patient-reported outcomes, health services research and patient engagement. Our goal is to serve as the Scientific and Data Research Center for the COPE-AKI Consortium. Specifically, we will 1) establish an efficient and rigorous process for designing the Consortium study, including protocol development and adaptation of an existing web-based data collection system; 2) provide comprehensive expertise for data management and analysis within the Consortium; and 3) provide program coordination and administrative support throughout all phases of the study.